Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?
Weir
Matthew R
MR
University of Maryland School of Medicine, Baltimore, MD, USA.
Bakris
George L
GL
D000419:Albuminuria / Q000175:diagnosis*; D015415:Biomarkers; D002986:Clinical Trials as Topic / Q000592:standards*; D015331:Cohort Studies; D003928:Diabetic Nephropathies / Q000652:urine*; D006801:Humans; D007249:Inflammation; D007674:Kidney Diseases / Q000628:therapy / Q000652:urine*; D012107:Research Design; D012307:Risk Factors; D016896:Treatment Outcome
D015415:Biomarkers